BCRX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
180.3M
-17.4%
218.3M
+39.5%
156.4M
-61.5%
406.6M
+155.1%
159.4M
Cost of Revenue
1.6M
-59.0%
3.8M
-28.6%
5.4M
-43.5%
9.5M
+335.4%
2.2M
Gross Profit
178.7M
-16.6%
214.4M
+42.0%
151.0M
-62.0%
397.0M
+152.6%
157.2M
Operating Expenses
125.4M
+8.1%
115.9M
-86.4%
852.6M
+524.0%
136.6M
+7.1%
127.6M
R&D
58.2M
+12.0%
52.0M
-93.1%
758.1M
+1755.0%
40.9M
-8.4%
44.6M
SG&A
67.2M
+5.0%
64.0M
-32.3%
94.6M
-1.3%
95.8M
+15.4%
83.0M
Operating Income
53.3M
-45.8%
98.5M
+114.0%
-701598000
-369.4%
260.4M
+779.9%
29.6M
EBITDA
54.2M
-44.9%
98.4M
+114.0%
-700537000
-368.6%
260.8M
+771.4%
29.9M
Net Income
37.9M
-51.6%
78.4M
+110.9%
-721812000
-393.6%
245.8M
+1805.9%
12.9M
EPS (Basic)
$0.15
-51.6%
$0.31
+110.4%
$-2.98
-354.7%
$1.17
+1850.0%
$0.06
EPS (Diluted)
$0.14
-53.3%
$0.30
+110.1%
$-2.98
-366.1%
$1.12
+1766.7%
$0.06
Shares (Diluted)
267.6M
+0.9%
265.2M
+9.5%
242.3M
+10.5%
219.3M
-0.3%
219.9M
BioCryst Pharmaceuticals (BCRX) — Financials